LCD Reference Article Billing and Coding Article

Billing and Coding: Pharmacogenomics Testing

A58812

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
First Coast Service Options, Inc.	A and B MAC	09101 - MAC A	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09102 - MAC B	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09201 - MAC A	J - N	Puerto Rico Virgin Islands
First Coast Service Options, Inc.	A and B MAC	09202 - MAC B	J - N	Puerto Rico
First Coast Service Options, Inc.	A and B MAC	09302 - MAC B	J - N	Virgin Islands

Article Information

General Information

Article ID
A58812

Article Title
Billing and Coding: Pharmacogenomics Testing

Article Type
Billing and Coding

Original Effective Date
12/12/2021

Revision Effective Date
10/24/2024

Revision Ending Date
N/A

Retirement Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

Internet Only Manuals (IOMs):

CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual,
- Chapter 1, Part 2, Section 90.1 Pharmacogenomic Testing to Predict Warfarin Responsiveness
CMS IOM Publication 100-04, Medicare Claims Processing Manual,
- Chapter 1, Section 60 Provider Billing of Non-covered Charges on Institutional Claims
- Chapter 16 Laboratory Services
- Chapter 23, Section 20.9 National Correct Coding Initiative (NCCI), Section 20.9.1.1 Instructions for Codes With Modifiers (A/B MACs (B) Only) and Section 40 Clinical Diagnostic Laboratory Fee Schedule

National Correct Coding Initiative (NCCI):

Medicare NCCI Policy Manual,
- Chapter 10 Pathology/Laboratory Services, (A) Introduction and (F) Molecular Pathology

Social Security Act (Title XVIII) Standard References:

Title XVIII of the Social Security Act, Section 1833(e) states that no payment shall be made to any provider of services or other person under this part unless there has been furnished such information as may be necessary in order to determine the amounts due such provider or other person under this part for the period with respect to which the amounts are being paid or for any prior period.

Title XVIII of the Social Security Act, Section 1834A(d) This section addresses payment for new advanced diagnostic laboratory tests.

Code of Federal Regulations (CFR) References:

CFR, Title 42, Volume 3, Chapter IV, Part 414.50 Physician or other supplier billing for diagnostic tests performed or interpreted by a physician who does not share a practice with the billing physician or other supplier.
CFR, Title 42, Volume 3, Chapter IV, Part 414, Subpart G Payment for Clinical Diagnostic Laboratory Tests.

Article Guidance

Article Text

This Billing and Coding Article provides billing and coding guidance for Local Coverage Determination (LCD) L39073, Pharmacogenomics Testing. Please refer to the LCD for reasonable and necessary requirements.

Laboratory tests that investigate the same germline genetic content, for the same genetic information, that has already been tested in the same Medicare beneficiary is duplicative and should not be reported.

Examples of germline tests include (but are not limited to) single gene and specific gene panel tests for: hereditary cancer syndromes or cancer predisposition, inherited disorders, and pharmacogenomics/cytochrome P450 testing.

Providers should take reasonable measures to be aware of what, if any, germline testing a beneficiary has had prior to billing for germline testing so as to avoid billing Medicare for services that are not reasonable and necessary. Clinicians who order germline testing may wish to be aware of whether the test that they are ordering is covered under Medicare and may wish to verify that they are not ordering repeat germline testing.

Germline testing, including panels containing some genetic content already tested in the same Medicare beneficiary, may be considered reasonable and necessary if there is established clinical utility in the remaining, non-duplicative genetic components of the test.

Coding Guidance

Notice: It is not appropriate to bill Medicare for services that are not covered (as described by the entire LCD) as if they are covered. When billing for non-covered services, use the appropriate modifier.

CPT codes 81355 (VKORC1) and 81227 (CYP2C9) are not considered reasonable and necessary for warfarin testing. Please refer to the CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2, Section 90.1 Pharmacogenomic Testing to Predict Warfarin Responsiveness.

If a treating clinician orders a single gene test or a test for a particular allele(s), but as a matter of operational practicality, the laboratory tests that single gene or allele on a platform that looks for variants in other genes/alleles as well, that particular test done in that particular instance is considered a single gene/allele test for coverage purposes. In this scenario the provider may bill for the component of the test that was reasonable and necessary (in this example, the single gene test).

Genes can be assayed serially or in parallel. Genes assayed on the same date of service are considered to be assayed in parallel if the result of 1 assay does not affect the decision to complete the assay on another gene, and the 2 genes are being tested for the same indication. Genes assayed on the same date of service are considered to be assayed serially when there is a reflexive decision component where the results of the analysis of 1 or more genes determines whether the results of additional analyses are reasonable and necessary. If 2 or more genes are tested, please refer to the Molecular Pathology and Genetic Testing Article A58918 for multi-gene testing.

When billing Part B claims, the drug or drugs in consideration for use that require the use of the PHARMACOGENOMICS (PGx) test must be submitted in the applicable detail line 2400 loop.

When billing CPT code 81418, the following information should be provided:

List the names of the specific genes that are tested in addition to genes CYP2C19 and CYP2D6 in the comment/narrative field for the following claim field/types:
- Part A Claims:
  - Loop SV202-7 for the 837I electronic claim
  - Block 80 for the UB04 claim form
- Part B Claims:
  - Loop 2400 or SV101-7 for the 5010A1 837P
  - Box 19 for the paper claim

NOTE: Testing MUST be for at least 6 genes per the CPT code descriptor for 81418: Drug metabolism (e.g., pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis.

The following 2 tables represent relevant gene/drug associations. Table 1 is from CPIC and Table 2 is from FDA sources.

Table 1. Current CPIC guidelines as of October 26, 2022:

Gene/Test	CPT Code	Intended use for Drug	Brand Name
CFTR	81220	ivacaftor	Kalydeco
CYP2B6	81479, 0349U, 0392U, 0423U	efavirenz, sertraline	Sustiva, Zoloft
CYP2C19	81225, 81418, 0349U, 0423U	clopidogrel, voriconazole	Plavix, Vfend
CYP2C19	81225, 81418, 0349U, 0423U	PPIs (class): omeprazole, lansoprazole, pantoprazole, dexlansoprazole	Prilosec, Prevacid, Protonix, Dexilant
CYP2C19	81225, 81418, 0349U, 0423U	SSRIs (class): citalopram, escitalopram, fluvoxamine, paroxetine, sertraline	Celexa, Lexapro, Luvox, Paxil, Zoloft
CYP2C19	81225, 81418, 0349U, 0423U	Tricyclic antidepressants (class): amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, trimipramine	Anafranil, Norpramin, Silenor, Pamelor, Surmontil
CYP2C9	81227, 0349U, 0423U	phenytoin, fosphenytoin	Dilantin, Cerebyx
CYP2C9	81227, 0349U, 0423U	NSAIDs (class): celecoxib, flurbiprofen, ibuprofen, lornoxicam, meloxicam, piroxicam, tenoxicam	Celebrex, Ocufen, Chlortenoxicam, Mobic, Feldene, Mobiflex
CYP2C9	81227, 0349U, 0423U	fluvastatin	Lescol
HLA-B	81381, 81374, 0349U, 0423U	abacavir, allopurinol, oxcarbazepine, phenytoin, carbamazepine, fosphenytoin	Ziagen, Zyloprim, Aloprim, Trileptal, Oxtellar, Dilantin, Tegretol, Cerebyx
CYP4F2	81479, 0349U	warfarin	Jantoven, Coumadin
CYP2D6	81226, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 0349U, 0423U	atomoxetine, codeine, ondansetron, tropisetron, tamoxifen, tramadol, hydrocodone	Strattera, Zofran, Soltamox, Ultram
CYP2D6	81226, 81418, 0392U, 0349U, 0423U	venlafaxine	Effexor
CYP2D6	81226, 81418, 0392U, 0349U, 0423U	vortioxetine	Trintellix
CYP2D6	81226, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 0349U, 0423U	SSRIs (class): citalopram, escitalopram, fluvoxamine, paroxetine, sertraline	Celexa, Lexapro, Luvox, Paxil, Zoloft
CYP2D6	81226, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 0349U, 0423U	Tricyclic antidepressants (class): amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, trimipramine	Anafranil, Norpramin, Silenor, Pamelor, Surmontil
CYP3A5	81231, 0349U, 0423U	tacrolimus	Prograf, Protopic
DPYD	81232, 0349U	Fluoropyrimidines (class): fluorouracil, capecitabine	Adrucil, Xeloda
G6PD	81247	rasburicase	Elitek
G6PD	81247	dapsone, methylene blue, nitrofurantoin, pegloticase, primaquine, tafenoquine	Aczone, Provayblue, Furadantin, Macrobid, Macrodantin, Krystexxa, Primaquine, Arakoda, Krintafel
HLA-A	81381, 81374, 0349U, 0423U	carbamazepine	Tegretol
IFNL3	81283	peginterferon alfa-2a, peginterferon alfa-2b	Pegasys, Pegintron, Sylatron
IFNL4	81479, 0349U	peginterferon alfa-2a, peginterferon alfa-2b	Pegasys, Pegintron, Sylatron
RYR1	81406	Volatile anesthetics (class): desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine	Suprane, Ethrane, Fluothane, Forane, Penthrox, Ultane, Anectine, Quelicin
CACNA1S	81479	Volatile anesthetics (class): desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine	Suprane, Ethrane, Fluothane, Forane, Penthrox, Ultane, Anectine, Quelicin
SLCO1B1	81328, 0349U, 0423U	Statins (class): simvastatin, pravastatin, atorvastatin, lovastatin, rosuvastatin, fluvastatin, pitavastatin	Zocor, FloLipid, Pravachol, Lipitor, Altoprev, Crestor, Lescol, Livalo
NUDT15	81306, 0286U, 0349U	Thiopurines (class): mercaptopurine, azathioprine, thioguanine	Purixan, Azasan, Tabloid
TPMT	81335, 0349U	Thiopurines (class): mercaptopurine, azathioprine, thioguanine	Purixan, Azasan, Tabloid
UGT1A1	81350, 0349U	atazanavir	Reyataz
MT-RNR1	81401	Aminoglycosides (class): gentamicin, amikacin, paromomycin, streptomycin, plazomicin, tobramycin	Arikayce, Zemdri
ABCG2	0193U, 0423U	rosuvastatin	Crestor

Table 2. Table of PHARMACOGENOMIC associations from the FDA for which the data support therapeutic recommendations or a potential impact on safety or response (last updated October 26, 2022):

Gene	CPT Code	Drug	Brand Name	Affected Subgroups+
BCHE	81479	mivacurium	Mivacurium chloride	intermediate or poor metabolizers
BCHE	81479	succinylcholine	Anectine	intermediate or poor metabolizers
CYP2B6	81479, 0349U, 0423U	efavirenz	Sustiva	poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	brivaracetam	Briviact	intermediate or poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	citalopram	Celexa	poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	clobazam	Onfi	intermediate or poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	clopidogrel	Plavix	intermediate or poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	flibanserin	Addyi	poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	pantoprazole	Protonix	Intermediate or poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	voriconazole	Vfend	intermediate or poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	abrocitinib	Cibinqo	poor metabolizers
CYP2C19	81225, 81418, 0349U, 0423U	mavacamten	Camzyos	intermediate or poor metabolizers
CYP2C19 and/or UGT2B17	81225, 81418, 0349U, 0423U	belzutifan	Cibinqo	poor metabolizers
CYP2C9	81227, 0349U, 0423U	celecoxib	Celebrex	poor metabolizers or *3 carriers
CYP2C9	81227, 0349U, 0423U	dronabinol	Marinol	intermediate or poor metabolizers
CYP2C9	81227, 0349U, 0423U	erdafitinib	Balversa	3/3 (poor metabolizers)
CYP2C9	81227, 0349U, 0423U	flurbiprofen	Ansaid	poor metabolizers or *3 carriers
CYP2C9	81227, 0349U, 0423U	fosphenytoin	Cerebyx	intermediate or poor metabolizers
CYP2C9	81227, 0349U, 0423U	meloxicam	Mobic	poor metabolizers or *3 carriers
CYP2C9	81227, 0349U, 0423U	nateglinide		poor metabolizers
CYP2C9	81227, 0349U, 0423U	phenytoin	Dilantin	intermediate or poor metabolizers
CYP2C9	81227, 0349U, 0423U	piroxicam	Feldene	intermediate or poor metabolizers
CYP2C9	81227, 0349U, 0423U	siponimod	Mayzent	intermediate or poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	amphetamine	Adderall	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	aripiprazole	Abilify	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	aripiprazole lauroxil	Aristada	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	atomoxetine	Strattera	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	brexpiprazole	Rexulti	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	clozapine	Clozaril, FazaClo, Versacloz	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	codeine		ultrarapid metabolizers, poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	deutetrabenazine	Austedo	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	eliglustat	Cerdelga	ultrarapid, normal, intermediate, or poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	gefitinib	Iressa	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	Iloperidone	Fanapt	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	lofexidine	Lucemyra	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	meclizine	Antivert	ultrarapid, intermediate, or poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	metoclopramide	Reglan	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	pimozide	Orap	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	propafenone	Rythmol	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	tetrabenazine	Xenazine	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	thioridazine	Mellaril	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	tramadol	Ultram	ultrarapid metabolizers, or poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	valbenazine	Ingrezza	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	venlafaxine	Effexor	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	vortioxetine	Trintellix	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	carvedilol	Coreg	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	cevimeline	Evoxac	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	perphenazine	Trilafon	poor metabolizers
CYP2D6	81226, 81418, 0349U, 0423U	tolterodine	Detrol	poor metabolizers
CYP2D6	81226, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 0349U, 0423U	oliceridine	Olinvyk	poor metabolizers
CYP2D6	81226, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 0349U, 0423U	pitolisant	Wakix	poor metabolizers
CYP3A5	81231, 0349U, 0423U	tacrolimus	Prograf	intermediate or normal metabolizers
CYP4F2	81479, 0349U	warfarin	Coumadin	V433M variant carriers
DPYD	81232, 0349U	capecitabine	Xeloda	intermediate or poor metabolizers
DPYD	81232, 0349U	fluorouracil	Fluoroplex, Tolak, Efudex	intermediate or poor metabolizer
HLA-A	81381, 81374, 0349U, 0423U	carbamazepine	Tegretol	*31:01 allele positive
HLA-B	81381, 81374, 0349U, 0423U	abacavir	Ziagen	*57:01 allele positive
HLA-B	81381, 81374, 0349U, 0423U	carbamazepine	Tegretol	*15:02 allele positive
HLA-B	81381, 81374, 0349U, 0423U	fosphenytoin	Cerebyx	*15:02 allele positive
HLA-B	81381, 81374, 0349U, 0423U	allopurinol	Zyloprim, Aloprim	*58:01 allele positive
HLA-B	81381, 81374, 0349U, 0423U	oxcarbazepine	Trileptal, Oxtellar	*15:02 allele positive
HLA-B	81381, 81374, 0349U, 0423U	pazopanib	Votrient	*57:01 allele positive
HLA-B	81381, 81374, 0349U, 0423U	phenytoin	Dilantin	*15:02 allele positive
HLA-DQA1	81383, 81377	lapatinib	Tykerb	*02:01 allele positive
HLA-DRB1	81383, 81377	lapatinib	Tykerb	*07:01 allele positive
NAT2	81479	amifampridine	Firdapse, Ruzurgi	poor metabolizers
NAT2	81479	amifampridine phosphate		poor metabolizers
Nonspecific (NAT)	81479	isoniazid		poor metabolizers
Nonspecific (NAT)	81479	procainamide	Pronestyl, Procan	poor metabolizers
Nonspecific (NAT)	81479	sulfamethoxazole and trimethoprim	Sulfatrim, Bactrim	poor metabolizers
Nonspecific (NAT)	81479	sulfasalazine	Azulfidine	poor metabolizers
SLCO1B1	81328, 0349U, 0423U	simvastatin	FloLipid, Zocor	521 TC or 521 CC (intermediate or poor function transporters)
NUDT15 and/or TPMT	81306, 81335, 0286U, 0349U	azathioprine	Imuran, Azasan	intermediate or poor metabolizers
NUDT15 and/or TPMT	81306, 81335, 0286U, 0349U	mercaptopurine	Purixan, Purinethol	intermediate or poor metabolizers
NUDT15 and/or TPMT	81306, 81335, 0286U, 0349U	thioguanine	Tabloid	intermediate or poor metabolizers
UGT1A1	81350, 0349U	belinostat	Beleodaq	28/28 (poor metabolizers)
UGT1A1	81350, 0349U	irinotecan	Camptosar	1/6, 1/28 (intermediate metabolizers) or 6/6, 6/28, 28/28 (poor metabolizers)
UGT1A1	81350, 0349U	nilotinib	Tasigna	28/28 (poor metabolizers)
UGT1A1	81350, 0349U	pazopanib	Votrient	28/28 (poor metabolizers)
UGT1A1	81350, 0349U	sacituzumabgovitecan-hziy	Trodelvy	28/28 (poor metabolizers)

The CPT codes relevant to the related LCD are listed in the coding section below. If no CPT code is available for the gene(s) being tested, the unlisted molecular pathology procedure code 81479 should be used as indicated below.

Utilization Parameters

Germline testing may be performed once in a lifetime per beneficiary.

Documentation Requirements

All documentation must be maintained in the patient’s medical record and made available to the contractor upon request.
Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service[s]). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
The provider performing the service must have a record of what drug(s) is/are being considered and for what indication to ensure the test performed is reasonable and necessary.
The clinical record must clearly show the use of or intent to prescribe a drug that has known drug-gene interactions that require a PGx test to be ordered to define the safe use of that drug in that patient.

Coding Information

When more than 2 codes from this list are submitted for the same beneficiary on the same date of service, the claims processing system will deny every code submitted after the first 2 services. However, if a lab runs more than 2 distinct procedural services from this list on a single date of service, then the lab must use the 59 modifier with each additional service billed as an attestation that it is a distinct procedural service. Billing the 59 modifier may result in a request for medical records.

The molecular pathology codes include all analytical services performed during the test (e.g., cell lysis, nucleic acid stabilization, extraction, digestion, amplification, and detection).

Response To Comments

Number	Comment	Response
1

Coding Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

CPT/HCPCS Codes

Expand All | Collapse All

Please accept the License to see the codes.

CPT/HCPCS Modifiers

Expand All | Collapse All

Group 1

(1 Code)

Group 1 Paragraph

N/A

Group 1 Codes

Code	Description
59	DISTINCT PROCEDURAL SERVICE: UNDER CERTAIN CIRCUMSTANCES, THE PHYSICIAN MAY NEED TO INDICATE THAT A PROCEDURE OR SERVICE WAS DISTINCT OR INDEPENDENT FROM OTHER SERVICES PERFORMED ON THE SAME DAY. MODIFIER -59 IS USED TO IDENTIFY PROCEDURES/SERVICES THAT ARE NOT NORMALLY REPORTED TOGETHER, BUT ARE APPROPRIATE UNDER THE CIRCUMSTANCES. THIS MAY REPRESENT A DIFFERENT SESSION OR PATIENT ENCOUNTER, DIFFERENT PROCEDURE OR SURGERY, DIFFERNET SITE OR ORGAN SYSTEM, SEPARATE INCISION/EXCISION, SEPARATE LESION, OR SEPARATE INJURY (OR AREA OF INJURY IN EXTENSIVE INJURIES) NOT ORDINARILY ENCOUNTERED OR PERFORMED ON THE SAME DAY BY THE SAME PHYSICIAN. HOWEVER, WHAN ANOTHER ALREADY ESTABLISHED MODIFIER IS APPROPRIATE IT SHOULD BE USED RATHER THAN MODIFIER -59. ONLY IF NO MORE DESCRIPTIVE MODIFIER IS AVAILABLE, AND THE USE OF MODIFIER -59 BEST EXPLAINS THE CIRCUMSTANCES, SHOULD MODIFIER -59 BE USED. MODIFIER CODE 09959 MAY BE USED AS AN ALTERNATE TO MODIFIER -59.

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

(1 Code)

Group 1 Paragraph

It is the provider’s responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

The following ICD-10-CM code supports medical necessity and provides coverage for CPT code: 81220.

Group 1 Codes

Code	Description
E84.8	Cystic fibrosis with other manifestations

Group 2

(100 Codes)

Group 2 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81225, 81418, 0349U, and 0423U.

Group 2 Codes

Code	Description
B37.81	Candidal esophagitis
B37.89	Other sites of candidiasis
B44.0	Invasive pulmonary aspergillosis
B48.8*	Other specified mycoses
C25.4*	Malignant neoplasm of endocrine pancreas
C64.1*	Malignant neoplasm of right kidney, except renal pelvis
C64.2*	Malignant neoplasm of left kidney, except renal pelvis
C65.1*	Malignant neoplasm of right renal pelvis
C65.2*	Malignant neoplasm of left renal pelvis
C66.1*	Malignant neoplasm of right ureter
C66.2*	Malignant neoplasm of left ureter
C67.0*	Malignant neoplasm of trigone of bladder
C67.1*	Malignant neoplasm of dome of bladder
C67.2*	Malignant neoplasm of lateral wall of bladder
C67.3*	Malignant neoplasm of anterior wall of bladder
C67.4*	Malignant neoplasm of posterior wall of bladder
C67.5*	Malignant neoplasm of bladder neck
C67.6*	Malignant neoplasm of ureteric orifice
C67.7*	Malignant neoplasm of urachus
C67.8*	Malignant neoplasm of overlapping sites of bladder
C68.0*	Malignant neoplasm of urethra
C68.1*	Malignant neoplasm of paraurethral glands
C68.8*	Malignant neoplasm of overlapping sites of urinary organs
C7A.093*	Malignant carcinoid tumor of the kidney
D13.7*	Benign neoplasm of endocrine pancreas
D18.02*	Hemangioma of intracranial structures
D32.0*	Benign neoplasm of cerebral meninges
D32.1*	Benign neoplasm of spinal meninges
D33.0*	Benign neoplasm of brain, supratentorial
D33.1*	Benign neoplasm of brain, infratentorial
D33.3*	Benign neoplasm of cranial nerves
D33.4*	Benign neoplasm of spinal cord
D33.7*	Benign neoplasm of other specified parts of central nervous system
E16.4	Increased secretion of gastrin
E31.20	Multiple endocrine neoplasia [MEN] syndrome, unspecified
E31.8	Other polyglandular dysfunction
F32.1	Major depressive disorder, single episode, moderate
F32.2	Major depressive disorder, single episode, severe without psychotic features
F32.3	Major depressive disorder, single episode, severe with psychotic features
F32.4	Major depressive disorder, single episode, in partial remission
F32.81	Premenstrual dysphoric disorder
F32.9	Major depressive disorder, single episode, unspecified
F33.1	Major depressive disorder, recurrent, moderate
F33.2	Major depressive disorder, recurrent severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms
F33.41	Major depressive disorder, recurrent, in partial remission
F33.9	Major depressive disorder, recurrent, unspecified
F40.01	Agoraphobia with panic disorder
F40.11	Social phobia, generalized
F41.0	Panic disorder [episodic paroxysmal anxiety]
F41.1	Generalized anxiety disorder
F43.11	Post-traumatic stress disorder, acute
F43.12	Post-traumatic stress disorder, chronic
F52.0*	Hypoactive sexual desire disorder
F60.5	Obsessive-compulsive personality disorder
G40.101	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus
G40.109	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus
G40.111	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus
G40.119	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus
G40.201	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus
G40.209	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus
G40.811	Lennox-Gastaut syndrome, not intractable, with status epilepticus
G40.812	Lennox-Gastaut syndrome, not intractable, without status epilepticus
G40.813	Lennox-Gastaut syndrome, intractable, with status epilepticus
G40.814	Lennox-Gastaut syndrome, intractable, without status epilepticus
G47.09	Other insomnia
I20.0	Unstable angina
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
I21.29	ST elevation (STEMI) myocardial infarction involving other sites
I21.4	Non-ST elevation (NSTEMI) myocardial infarction
I21.A1	Myocardial infarction type 2
I21.A9	Other myocardial infarction type
I21.B	Myocardial infarction with coronary microvascular dysfunction
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites
I25.2	Old myocardial infarction
I42.1	Obstructive hypertrophic cardiomyopathy
I69.30	Unspecified sequelae of cerebral infarction
K21.00	Gastro-esophageal reflux disease with esophagitis, without bleeding
K21.01	Gastro-esophageal reflux disease with esophagitis, with bleeding
K21.9	Gastro-esophageal reflux disease without esophagitis
K22.10	Ulcer of esophagus without bleeding
K22.11	Ulcer of esophagus with bleeding
K25.9	Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation
K26.6	Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K26.7	Chronic duodenal ulcer without hemorrhage or perforation
K26.9	Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation
L20.89	Other atopic dermatitis
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
Z98.61	Coronary angioplasty status
Z98.62	Peripheral vascular angioplasty status

Group 2 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Dual diagnosis requirement: ICD-10-CM code B48.8 must be reported with ICD-10-CM code Z16.32.
*Dual diagnosis requirement: ICD-10-CM code F52.0 must be reported with ICD-10-CM code N95.8.
*Dual diagnosis requirement: ICD-10-CM code Q85.83 must be billed with ICD-10-CM code C25.4, C64.1, C64.2, C65.1, C65.2, C66.1, C66.2, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C68.0, C68.1, C68.8, C7A.093, D13.7, D18.02, D32.0, D32.1, D33.0, D33.1, D33.3, D33.4, OR D33.7.

Group 3

(31 Codes)

Group 3 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81226, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 0349U, and 0423U.

Group 3 Codes

Code	Description
C50.919*	Malignant neoplasm of unspecified site of unspecified female breast
C50.929*	Malignant neoplasm of unspecified site of unspecified male breast
F32.1	Major depressive disorder, single episode, moderate
F32.2	Major depressive disorder, single episode, severe without psychotic features
F32.3	Major depressive disorder, single episode, severe with psychotic features
F32.4	Major depressive disorder, single episode, in partial remission
F32.81	Premenstrual dysphoric disorder
F32.9	Major depressive disorder, single episode, unspecified
F33.1	Major depressive disorder, recurrent, moderate
F33.2	Major depressive disorder, recurrent severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms
F33.41	Major depressive disorder, recurrent, in partial remission
F33.9	Major depressive disorder, recurrent, unspecified
F40.01	Agoraphobia with panic disorder
F40.11	Social phobia, generalized
F41.0	Panic disorder [episodic paroxysmal anxiety]
F41.1	Generalized anxiety disorder
F43.11	Post-traumatic stress disorder, acute
F43.12	Post-traumatic stress disorder, chronic
F60.5	Obsessive-compulsive personality disorder
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type
F90.2	Attention-deficit hyperactivity disorder, combined type
F90.8	Attention-deficit hyperactivity disorder, other type
G47.09	Other insomnia
G47.411	Narcolepsy with cataplexy
G47.419	Narcolepsy without cataplexy
G89.11	Acute pain due to trauma
G89.18	Other acute postprocedural pain
G89.29	Other chronic pain
R11.2*	Nausea with vomiting, unspecified
R52	Pain, unspecified

Group 3 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Report ICD-10-CM code C50.919 or C50.929 with ICD-10-CM code Z17.0 or Z17.1 to identify estrogen receptor status.

*Dual diagnosis requirement: ICD-10-CM code R11.2 must be reported with ICD-10-CM code Z48.89, Z51.0, or Z92.21.

Group 4

(79 Codes)

Group 4 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81226, 81418, 0349U, 0392U, and 0423U.

Group 4 Codes

Code	Description
C34.90*	Malignant neoplasm of unspecified part of unspecified bronchus or lung
E75.22	Gaucher disease
F11.23	Opioid dependence with withdrawal
F20.0	Paranoid schizophrenia
F20.1	Disorganized schizophrenia
F20.2	Catatonic schizophrenia
F20.3	Undifferentiated schizophrenia
F20.5	Residual schizophrenia
F20.81	Schizophreniform disorder
F20.89	Other schizophrenia
F31.0	Bipolar disorder, current episode hypomanic
F31.11	Bipolar disorder, current episode manic without psychotic features, mild
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate
F31.13	Bipolar disorder, current episode manic without psychotic features, severe
F31.2	Bipolar disorder, current episode manic severe with psychotic features
F31.31	Bipolar disorder, current episode depressed, mild
F31.32	Bipolar disorder, current episode depressed, moderate
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features
F31.61	Bipolar disorder, current episode mixed, mild
F31.62	Bipolar disorder, current episode mixed, moderate
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic
F31.73	Bipolar disorder, in partial remission, most recent episode manic
F31.75	Bipolar disorder, in partial remission, most recent episode depressed
F31.77	Bipolar disorder, in partial remission, most recent episode mixed
F32.1	Major depressive disorder, single episode, moderate
F32.2	Major depressive disorder, single episode, severe without psychotic features
F32.3	Major depressive disorder, single episode, severe with psychotic features
F32.4	Major depressive disorder, single episode, in partial remission
F32.9	Major depressive disorder, single episode, unspecified
F33.1	Major depressive disorder, recurrent, moderate
F33.2	Major depressive disorder, recurrent severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms
F33.41	Major depressive disorder, recurrent, in partial remission
F33.9	Major depressive disorder, recurrent, unspecified
F40.01	Agoraphobia with panic disorder
F40.11	Social phobia, generalized
F41.0	Panic disorder [episodic paroxysmal anxiety]
F41.1	Generalized anxiety disorder
F43.11	Post-traumatic stress disorder, acute
F43.12	Post-traumatic stress disorder, chronic
F60.5	Obsessive-compulsive personality disorder
F84.0	Autistic disorder
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type
F90.2	Attention-deficit hyperactivity disorder, combined type
F90.8	Attention-deficit hyperactivity disorder, other type
F95.2	Tourette's disorder
G10	Huntington's disease
G24.01	Drug induced subacute dyskinesia
G47.411	Narcolepsy with cataplexy
G47.419	Narcolepsy without cataplexy
G89.11	Acute pain due to trauma
G89.18	Other acute postprocedural pain
G89.29	Other chronic pain
I10	Essential (primary) hypertension
I48.0	Paroxysmal atrial fibrillation
I48.11	Longstanding persistent atrial fibrillation
I48.19	Other persistent atrial fibrillation
I50.1	Left ventricular failure, unspecified
I50.20	Unspecified systolic (congestive) heart failure
I50.30	Unspecified diastolic (congestive) heart failure
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure
I50.89	Other heart failure
I50.9	Heart failure, unspecified
K21.00	Gastro-esophageal reflux disease with esophagitis, without bleeding
K21.01	Gastro-esophageal reflux disease with esophagitis, with bleeding
K21.9	Gastro-esophageal reflux disease without esophagitis
K31.84*	Gastroparesis
M35.00	Sjogren syndrome, unspecified
N39.41*	Urge incontinence
N39.46*	Mixed incontinence
R11.2*	Nausea with vomiting, unspecified
R45.851*	Suicidal ideations
R52	Pain, unspecified
T75.3XXA	Motion sickness, initial encounter
T75.3XXD	Motion sickness, subsequent encounter
T75.3XXS	Motion sickness, sequela

Group 4 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Dual diagnosis requirement: ICD-10-CM code C34.90 must be reported with ICD-10-CM code Z92.21 to identify personal history of antineoplastic chemotherapy.

*Report ICD-10-CM code K31.84 with an ICD-10-CM code for diabetes mellitus (E08.43, E09.43, E10.43, E11.43, or E13.43).

*When reporting ICD-10-CM codes N39.41 or N39.46, also report ICD-10-CM code N32.81 for any associated overactive bladder.

*Dual diagnosis requirement: ICD-10-CM code R11.2 must be reported with ICD-10-CM code Z48.89, Z51.0, or Z92.21.

*Dual diagnosis requirement: ICD-10-CM code R45.851 must be reported with 1 of the following ICD-10-CM codes to identify schizophrenia: F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, or F20.89 (these ICD-10-CM codes for schizophrenia may also be reported as stand-alone codes).

Group 5

(24 Codes)

Group 5 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81227, 0349U, and 0423U.

Group 5 Codes

Code	Description
E78.00	Pure hypercholesterolemia, unspecified
E78.01	Familial hypercholesterolemia
E78.1	Pure hyperglyceridemia
E78.2	Mixed hyperlipidemia
G40.201	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus
G40.209	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus
G40.301	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus
G40.309	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus
G40.311	Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.319	Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.401	Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus
G40.409	Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus
G40.411	Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.419	Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris
M06.8A	Other specified rheumatoid arthritis, other specified site
M19.09	Primary osteoarthritis, other specified site
M19.29	Secondary osteoarthritis, other specified site
T38.3X5A	Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
Z48.811	Encounter for surgical aftercare following surgery on the nervous system
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
Z86.79	Personal history of other diseases of the circulatory system

Group 6

(3 Codes)

Group 6 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81231, 0349U, and 0423U.

Group 6 Codes

Code	Description
Z94.0	Kidney transplant status
Z94.1	Heart transplant status
Z94.4	Liver transplant status

Group 7

(7 Codes)

Group 7 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81232 and 0349U.

Group 7 Codes

Code	Description
C16.9	Malignant neoplasm of stomach, unspecified
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C25.9	Malignant neoplasm of pancreas, unspecified
C50.919*	Malignant neoplasm of unspecified site of unspecified female breast
C50.929*	Malignant neoplasm of unspecified site of unspecified male breast

Group 7 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Report ICD-10-CM code C50.919 or C50.929 with ICD-10-CM code Z17.0 or Z17.1 to identify estrogen receptor status.

Group 8

(168 Codes)

Group 8 Paragraph

The following ICD-10-CM code supports medical necessity and provides coverage for CPT code: 81247

Group 8 Codes

Code	Description
B51.0	Plasmodium vivax malaria with rupture of spleen
B51.8	Plasmodium vivax malaria with other complications
B51.9	Plasmodium vivax malaria without complication
D74.8	Other methemoglobinemias
E79.9*	Disorder of purine and pyrimidine metabolism, unspecified
L70.0	Acne vulgaris
M1A.0110	Idiopathic chronic gout, right shoulder, without tophus (tophi)
M1A.0111	Idiopathic chronic gout, right shoulder, with tophus (tophi)
M1A.0120	Idiopathic chronic gout, left shoulder, without tophus (tophi)
M1A.0121	Idiopathic chronic gout, left shoulder, with tophus (tophi)
M1A.0210	Idiopathic chronic gout, right elbow, without tophus (tophi)
M1A.0211	Idiopathic chronic gout, right elbow, with tophus (tophi)
M1A.0220	Idiopathic chronic gout, left elbow, without tophus (tophi)
M1A.0221	Idiopathic chronic gout, left elbow, with tophus (tophi)
M1A.0310	Idiopathic chronic gout, right wrist, without tophus (tophi)
M1A.0311	Idiopathic chronic gout, right wrist, with tophus (tophi)
M1A.0320	Idiopathic chronic gout, left wrist, without tophus (tophi)
M1A.0321	Idiopathic chronic gout, left wrist, with tophus (tophi)
M1A.0410	Idiopathic chronic gout, right hand, without tophus (tophi)
M1A.0411	Idiopathic chronic gout, right hand, with tophus (tophi)
M1A.0420	Idiopathic chronic gout, left hand, without tophus (tophi)
M1A.0421	Idiopathic chronic gout, left hand, with tophus (tophi)
M1A.0510	Idiopathic chronic gout, right hip, without tophus (tophi)
M1A.0511	Idiopathic chronic gout, right hip, with tophus (tophi)
M1A.0520	Idiopathic chronic gout, left hip, without tophus (tophi)
M1A.0521	Idiopathic chronic gout, left hip, with tophus (tophi)
M1A.0610	Idiopathic chronic gout, right knee, without tophus (tophi)
M1A.0611	Idiopathic chronic gout, right knee, with tophus (tophi)
M1A.0620	Idiopathic chronic gout, left knee, without tophus (tophi)
M1A.0621	Idiopathic chronic gout, left knee, with tophus (tophi)
M1A.0710	Idiopathic chronic gout, right ankle and foot, without tophus (tophi)
M1A.0711	Idiopathic chronic gout, right ankle and foot, with tophus (tophi)
M1A.0720	Idiopathic chronic gout, left ankle and foot, without tophus (tophi)
M1A.0721	Idiopathic chronic gout, left ankle and foot, with tophus (tophi)
M1A.08X0	Idiopathic chronic gout, vertebrae, without tophus (tophi)
M1A.08X1	Idiopathic chronic gout, vertebrae, with tophus (tophi)
M1A.09X0	Idiopathic chronic gout, multiple sites, without tophus (tophi)
M1A.09X1	Idiopathic chronic gout, multiple sites, with tophus (tophi)
M1A.1110	Lead-induced chronic gout, right shoulder, without tophus (tophi)
M1A.1111	Lead-induced chronic gout, right shoulder, with tophus (tophi)
M1A.1120	Lead-induced chronic gout, left shoulder, without tophus (tophi)
M1A.1121	Lead-induced chronic gout, left shoulder, with tophus (tophi)
M1A.1210	Lead-induced chronic gout, right elbow, without tophus (tophi)
M1A.1211	Lead-induced chronic gout, right elbow, with tophus (tophi)
M1A.1220	Lead-induced chronic gout, left elbow, without tophus (tophi)
M1A.1221	Lead-induced chronic gout, left elbow, with tophus (tophi)
M1A.1310	Lead-induced chronic gout, right wrist, without tophus (tophi)
M1A.1311	Lead-induced chronic gout, right wrist, with tophus (tophi)
M1A.1320	Lead-induced chronic gout, left wrist, without tophus (tophi)
M1A.1321	Lead-induced chronic gout, left wrist, with tophus (tophi)
M1A.1410	Lead-induced chronic gout, right hand, without tophus (tophi)
M1A.1411	Lead-induced chronic gout, right hand, with tophus (tophi)
M1A.1420	Lead-induced chronic gout, left hand, without tophus (tophi)
M1A.1421	Lead-induced chronic gout, left hand, with tophus (tophi)
M1A.1510	Lead-induced chronic gout, right hip, without tophus (tophi)
M1A.1511	Lead-induced chronic gout, right hip, with tophus (tophi)
M1A.1520	Lead-induced chronic gout, left hip, without tophus (tophi)
M1A.1521	Lead-induced chronic gout, left hip, with tophus (tophi)
M1A.1610	Lead-induced chronic gout, right knee, without tophus (tophi)
M1A.1611	Lead-induced chronic gout, right knee, with tophus (tophi)
M1A.1620	Lead-induced chronic gout, left knee, without tophus (tophi)
M1A.1621	Lead-induced chronic gout, left knee, with tophus (tophi)
M1A.1710	Lead-induced chronic gout, right ankle and foot, without tophus (tophi)
M1A.1711	Lead-induced chronic gout, right ankle and foot, with tophus (tophi)
M1A.1720	Lead-induced chronic gout, left ankle and foot, without tophus (tophi)
M1A.1721	Lead-induced chronic gout, left ankle and foot, with tophus (tophi)
M1A.18X0	Lead-induced chronic gout, vertebrae, without tophus (tophi)
M1A.18X1	Lead-induced chronic gout, vertebrae, with tophus (tophi)
M1A.19X0	Lead-induced chronic gout, multiple sites, without tophus (tophi)
M1A.19X1	Lead-induced chronic gout, multiple sites, with tophus (tophi)
M1A.2110	Drug-induced chronic gout, right shoulder, without tophus (tophi)
M1A.2111	Drug-induced chronic gout, right shoulder, with tophus (tophi)
M1A.2120	Drug-induced chronic gout, left shoulder, without tophus (tophi)
M1A.2121	Drug-induced chronic gout, left shoulder, with tophus (tophi)
M1A.2210	Drug-induced chronic gout, right elbow, without tophus (tophi)
M1A.2211	Drug-induced chronic gout, right elbow, with tophus (tophi)
M1A.2220	Drug-induced chronic gout, left elbow, without tophus (tophi)
M1A.2221	Drug-induced chronic gout, left elbow, with tophus (tophi)
M1A.2310	Drug-induced chronic gout, right wrist, without tophus (tophi)
M1A.2311	Drug-induced chronic gout, right wrist, with tophus (tophi)
M1A.2320	Drug-induced chronic gout, left wrist, without tophus (tophi)
M1A.2321	Drug-induced chronic gout, left wrist, with tophus (tophi)
M1A.2410	Drug-induced chronic gout, right hand, without tophus (tophi)
M1A.2411	Drug-induced chronic gout, right hand, with tophus (tophi)
M1A.2420	Drug-induced chronic gout, left hand, without tophus (tophi)
M1A.2421	Drug-induced chronic gout, left hand, with tophus (tophi)
M1A.2510	Drug-induced chronic gout, right hip, without tophus (tophi)
M1A.2511	Drug-induced chronic gout, right hip, with tophus (tophi)
M1A.2520	Drug-induced chronic gout, left hip, without tophus (tophi)
M1A.2521	Drug-induced chronic gout, left hip, with tophus (tophi)
M1A.2610	Drug-induced chronic gout, right knee, without tophus (tophi)
M1A.2611	Drug-induced chronic gout, right knee, with tophus (tophi)
M1A.2620	Drug-induced chronic gout, left knee, without tophus (tophi)
M1A.2621	Drug-induced chronic gout, left knee, with tophus (tophi)
M1A.2710	Drug-induced chronic gout, right ankle and foot, without tophus (tophi)
M1A.2711	Drug-induced chronic gout, right ankle and foot, with tophus (tophi)
M1A.2720	Drug-induced chronic gout, left ankle and foot, without tophus (tophi)
M1A.2721	Drug-induced chronic gout, left ankle and foot, with tophus (tophi)
M1A.28X0	Drug-induced chronic gout, vertebrae, without tophus (tophi)
M1A.28X1	Drug-induced chronic gout, vertebrae, with tophus (tophi)
M1A.29X0	Drug-induced chronic gout, multiple sites, without tophus (tophi)
M1A.29X1	Drug-induced chronic gout, multiple sites, with tophus (tophi)
M1A.3110	Chronic gout due to renal impairment, right shoulder, without tophus (tophi)
M1A.3111	Chronic gout due to renal impairment, right shoulder, with tophus (tophi)
M1A.3120	Chronic gout due to renal impairment, left shoulder, without tophus (tophi)
M1A.3121	Chronic gout due to renal impairment, left shoulder, with tophus (tophi)
M1A.3210	Chronic gout due to renal impairment, right elbow, without tophus (tophi)
M1A.3211	Chronic gout due to renal impairment, right elbow, with tophus (tophi)
M1A.3220	Chronic gout due to renal impairment, left elbow, without tophus (tophi)
M1A.3221	Chronic gout due to renal impairment, left elbow, with tophus (tophi)
M1A.3310	Chronic gout due to renal impairment, right wrist, without tophus (tophi)
M1A.3311	Chronic gout due to renal impairment, right wrist, with tophus (tophi)
M1A.3320	Chronic gout due to renal impairment, left wrist, without tophus (tophi)
M1A.3321	Chronic gout due to renal impairment, left wrist, with tophus (tophi)
M1A.3410	Chronic gout due to renal impairment, right hand, without tophus (tophi)
M1A.3411	Chronic gout due to renal impairment, right hand, with tophus (tophi)
M1A.3420	Chronic gout due to renal impairment, left hand, without tophus (tophi)
M1A.3421	Chronic gout due to renal impairment, left hand, with tophus (tophi)
M1A.3510	Chronic gout due to renal impairment, right hip, without tophus (tophi)
M1A.3511	Chronic gout due to renal impairment, right hip, with tophus (tophi)
M1A.3520	Chronic gout due to renal impairment, left hip, without tophus (tophi)
M1A.3521	Chronic gout due to renal impairment, left hip, with tophus (tophi)
M1A.3610	Chronic gout due to renal impairment, right knee, without tophus (tophi)
M1A.3611	Chronic gout due to renal impairment, right knee, with tophus (tophi)
M1A.3620	Chronic gout due to renal impairment, left knee, without tophus (tophi)
M1A.3621	Chronic gout due to renal impairment, left knee, with tophus (tophi)
M1A.3710	Chronic gout due to renal impairment, right ankle and foot, without tophus (tophi)
M1A.3711	Chronic gout due to renal impairment, right ankle and foot, with tophus (tophi)
M1A.3720	Chronic gout due to renal impairment, left ankle and foot, without tophus (tophi)
M1A.3721	Chronic gout due to renal impairment, left ankle and foot, with tophus (tophi)
M1A.38X0	Chronic gout due to renal impairment, vertebrae, without tophus (tophi)
M1A.38X1	Chronic gout due to renal impairment, vertebrae, with tophus (tophi)
M1A.39X0	Chronic gout due to renal impairment, multiple sites, without tophus (tophi)
M1A.39X1	Chronic gout due to renal impairment, multiple sites, with tophus (tophi)
M1A.4110	Other secondary chronic gout, right shoulder, without tophus (tophi)
M1A.4111	Other secondary chronic gout, right shoulder, with tophus (tophi)
M1A.4120	Other secondary chronic gout, left shoulder, without tophus (tophi)
M1A.4121	Other secondary chronic gout, left shoulder, with tophus (tophi)
M1A.4210	Other secondary chronic gout, right elbow, without tophus (tophi)
M1A.4211	Other secondary chronic gout, right elbow, with tophus (tophi)
M1A.4220	Other secondary chronic gout, left elbow, without tophus (tophi)
M1A.4221	Other secondary chronic gout, left elbow, with tophus (tophi)
M1A.4310	Other secondary chronic gout, right wrist, without tophus (tophi)
M1A.4311	Other secondary chronic gout, right wrist, with tophus (tophi)
M1A.4320	Other secondary chronic gout, left wrist, without tophus (tophi)
M1A.4321	Other secondary chronic gout, left wrist, with tophus (tophi)
M1A.4410	Other secondary chronic gout, right hand, without tophus (tophi)
M1A.4411	Other secondary chronic gout, right hand, with tophus (tophi)
M1A.4420	Other secondary chronic gout, left hand, without tophus (tophi)
M1A.4421	Other secondary chronic gout, left hand, with tophus (tophi)
M1A.4510	Other secondary chronic gout, right hip, without tophus (tophi)
M1A.4511	Other secondary chronic gout, right hip, with tophus (tophi)
M1A.4520	Other secondary chronic gout, left hip, without tophus (tophi)
M1A.4521	Other secondary chronic gout, left hip, with tophus (tophi)
M1A.4610	Other secondary chronic gout, right knee, without tophus (tophi)
M1A.4611	Other secondary chronic gout, right knee, with tophus (tophi)
M1A.4620	Other secondary chronic gout, left knee, without tophus (tophi)
M1A.4621	Other secondary chronic gout, left knee, with tophus (tophi)
M1A.4710	Other secondary chronic gout, right ankle and foot, without tophus (tophi)
M1A.4711	Other secondary chronic gout, right ankle and foot, with tophus (tophi)
M1A.4720	Other secondary chronic gout, left ankle and foot, without tophus (tophi)
M1A.4721	Other secondary chronic gout, left ankle and foot, with tophus (tophi)
M1A.48X0	Other secondary chronic gout, vertebrae, without tophus (tophi)
M1A.48X1	Other secondary chronic gout, vertebrae, with tophus (tophi)
M1A.49X0	Other secondary chronic gout, multiple sites, without tophus (tophi)
M1A.49X1	Other secondary chronic gout, multiple sites, with tophus (tophi)
N30.00*	Acute cystitis without hematuria
N30.01*	Acute cystitis with hematuria

Group 8 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Dual Diagnosis Requirement: ICD-10-CM code N30.00 or N30.01 must be reported with ICD-10-CM code B95.2, B95.61, B95.62, B95.7, B96.1, B96.21, B96.22, B96.29, OR B96.89.

*Report ICD-10-CM code E79.9 with an ICD-10-CM code to identify leukemia, lymphoma, or solid tumor malignancy (C80.1, C95.90, C95.91, C95.92, C96.Z, C96.9, Z85.6, Z85.79, or Z85.9 as applicable) AND an ICD-10-CM code to identify anti-cancer therapy used (Z92.21, Z92.25, Z92.29, or Z92.3 as applicable).

Group 9

(23 Codes)

Group 9 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT code: 81283.

Group 9 Codes

Code	Description
B18.0*	Chronic viral hepatitis B with delta-agent
B18.1*	Chronic viral hepatitis B without delta-agent
B18.2*	Chronic viral hepatitis C
C43.0*	Malignant melanoma of lip
C43.111*	Malignant melanoma of right upper eyelid, including canthus
C43.112*	Malignant melanoma of right lower eyelid, including canthus
C43.121*	Malignant melanoma of left upper eyelid, including canthus
C43.122*	Malignant melanoma of left lower eyelid, including canthus
C43.21*	Malignant melanoma of right ear and external auricular canal
C43.22*	Malignant melanoma of left ear and external auricular canal
C43.31*	Malignant melanoma of nose
C43.39*	Malignant melanoma of other parts of face
C43.4*	Malignant melanoma of scalp and neck
C43.51*	Malignant melanoma of anal skin
C43.52*	Malignant melanoma of skin of breast
C43.59*	Malignant melanoma of other part of trunk
C43.61*	Malignant melanoma of right upper limb, including shoulder
C43.62*	Malignant melanoma of left upper limb, including shoulder
C43.71*	Malignant melanoma of right lower limb, including hip
C43.72*	Malignant melanoma of left lower limb, including hip
C43.8*	Malignant melanoma of overlapping sites of skin
C43.9*	Malignant melanoma of skin, unspecified
K73.9*	Chronic hepatitis, unspecified

Group 9 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Dual diagnosis requirement: ICD-10-CM code B18.0, B18.1, B18.2, or K73.9 must be reported with ICD-10-CM code K76.9 to indicate compensated liver disease.

*Dual diagnosis requirement: ICD-10-CM code C43.0, C43.111, C43.112, C43.121, C43.122, C43.21, C43.22, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.61, C43.62, C43.71, C43.72, C43.8, or C43.9 must be reported with ICD-10-CM code C77.9 to indicate nodal involvement.

Group 10

(9 Codes)

Group 10 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81306, 81335, 0286U, and 0349U.

Group 10 Codes

Code	Description
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse
C92.00	Acute myeloblastic leukemia, not having achieved remission
C92.01	Acute myeloblastic leukemia, in remission
C92.02	Acute myeloblastic leukemia, in relapse
M06.89	Other specified rheumatoid arthritis, multiple sites
M06.8A	Other specified rheumatoid arthritis, other specified site
Z94.0	Kidney transplant status

Group 11

(11 Codes)

Group 11 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81328, 0349U, and 0423U.

Group 11 Codes

Code	Description
E11.8*	Type 2 diabetes mellitus with unspecified complications
E11.9*	Type 2 diabetes mellitus without complications
E78.00	Pure hypercholesterolemia, unspecified
E78.01	Familial hypercholesterolemia
E78.1	Pure hyperglyceridemia
E78.2	Mixed hyperlipidemia
E78.49	Other hyperlipidemia
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris
Z86.39	Personal history of other endocrine, nutritional and metabolic disease
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
Z86.79	Personal history of other diseases of the circulatory system

Group 11 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Report ICD-10-CM code E11.8 or E11.9 with ICD-10-CM code(s) to indicate multiple risk factors for cardiovascular heart disease (e.g., E78.2, E78.49, I10, Z68.25-Z68.45, Z72.0, and/or Z82.49).

Group 12

(62 Codes)

Group 12 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81350 and 0349U.

Group 12 Codes

Code	Description
B20	Human immunodeficiency virus [HIV] disease
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C49.9*	Malignant neoplasm of connective and soft tissue, unspecified
C50.011*	Malignant neoplasm of nipple and areola, right female breast
C50.012*	Malignant neoplasm of nipple and areola, left female breast
C50.021*	Malignant neoplasm of nipple and areola, right male breast
C50.022*	Malignant neoplasm of nipple and areola, left male breast
C50.111*	Malignant neoplasm of central portion of right female breast
C50.112*	Malignant neoplasm of central portion of left female breast
C50.121*	Malignant neoplasm of central portion of right male breast
C50.122*	Malignant neoplasm of central portion of left male breast
C50.211*	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212*	Malignant neoplasm of upper-inner quadrant of left female breast
C50.221*	Malignant neoplasm of upper-inner quadrant of right male breast
C50.222*	Malignant neoplasm of upper-inner quadrant of left male breast
C50.311*	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312*	Malignant neoplasm of lower-inner quadrant of left female breast
C50.321*	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322*	Malignant neoplasm of lower-inner quadrant of left male breast
C50.411*	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412*	Malignant neoplasm of upper-outer quadrant of left female breast
C50.421*	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422*	Malignant neoplasm of upper-outer quadrant of left male breast
C50.511*	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512*	Malignant neoplasm of lower-outer quadrant of left female breast
C50.521*	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522*	Malignant neoplasm of lower-outer quadrant of left male breast
C50.611*	Malignant neoplasm of axillary tail of right female breast
C50.612*	Malignant neoplasm of axillary tail of left female breast
C50.621*	Malignant neoplasm of axillary tail of right male breast
C50.622*	Malignant neoplasm of axillary tail of left male breast
C50.811*	Malignant neoplasm of overlapping sites of right female breast
C50.812*	Malignant neoplasm of overlapping sites of left female breast
C50.821*	Malignant neoplasm of overlapping sites of right male breast
C50.822*	Malignant neoplasm of overlapping sites of left male breast
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1*	Malignant neoplasm of right renal pelvis
C65.2*	Malignant neoplasm of left renal pelvis
C66.1*	Malignant neoplasm of right ureter
C66.2*	Malignant neoplasm of left ureter
C67.0*	Malignant neoplasm of trigone of bladder
C67.1*	Malignant neoplasm of dome of bladder
C67.2*	Malignant neoplasm of lateral wall of bladder
C67.3*	Malignant neoplasm of anterior wall of bladder
C67.4*	Malignant neoplasm of posterior wall of bladder
C67.5*	Malignant neoplasm of bladder neck
C67.6*	Malignant neoplasm of ureteric orifice
C67.7*	Malignant neoplasm of urachus
C67.8*	Malignant neoplasm of overlapping sites of bladder
C67.9*	Malignant neoplasm of bladder, unspecified
C68.0*	Malignant neoplasm of urethra
C68.8*	Malignant neoplasm of overlapping sites of urinary organs
C84.40	Peripheral T-cell lymphoma, not elsewhere classified, unspecified site
C84.48	Peripheral T-cell lymphoma, not elsewhere classified, lymph nodes of multiple sites
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm
Z85.030	Personal history of malignant carcinoid tumor of large intestine
Z85.038	Personal history of other malignant neoplasm of large intestine
Z85.040	Personal history of malignant carcinoid tumor of rectum

Group 12 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Report ICD-10-CM code C49.9 with ICD-10-CM code Z92.21 to indicate prior chemotherapy.

*Report ICD-10-CM code C50.011, C50.012, C50.021, C50.022, C50.111, C50.112, C50.121, C50.122, C50.211, C50.212, C50.221, C50.222, C50.311, C50.312, C50.321, C50.322, C50.411, C50.412, C50.421, C50.422, C50.511, C50.512, C50.521, C50.522, C50.611, C50.612, C50.621, C50.622, C50.811, C50.812, C50.821, or C50.822 with an ICD-10-CM code to identify anti-cancer therapy used (Z92.21, Z92.25, Z92.29, or Z92.3 as applicable).

*Report ICD-10-CM code C65.1, C65.2, C66.1, C66.2, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, C68.0, or C68.8 with an ICD-10-CM code to identify anti-cancer therapy used (Z92.21, Z92.25, and/or Z92.29 as applicable).

Group 13

(46 Codes)

Group 13 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81374, 81381, 0349U, and 0423U.

Group 13 Codes

Code	Description
B20	Human immunodeficiency virus [HIV] disease
C49.9*	Malignant neoplasm of connective and soft tissue, unspecified
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
G40.101	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus
G40.109	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus
G40.111	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus
G40.119	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus
G40.201	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus
G40.209	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus
G40.301	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus
G40.309	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus
G40.311	Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.319	Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.401	Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus
G40.409	Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus
G40.411	Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.419	Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.801	Other epilepsy, not intractable, with status epilepticus
G40.802	Other epilepsy, not intractable, without status epilepticus
G40.803	Other epilepsy, intractable, with status epilepticus
G40.804	Other epilepsy, intractable, without status epilepticus
G50.0	Trigeminal neuralgia
M1A.00X0	Idiopathic chronic gout, unspecified site, without tophus (tophi)
M1A.00X1	Idiopathic chronic gout, unspecified site, with tophus (tophi)
M1A.09X0	Idiopathic chronic gout, multiple sites, without tophus (tophi)
M1A.09X1	Idiopathic chronic gout, multiple sites, with tophus (tophi)
M1A.40X0	Other secondary chronic gout, unspecified site, without tophus (tophi)
M1A.40X1	Other secondary chronic gout, unspecified site, with tophus (tophi)
M1A.49X0	Other secondary chronic gout, multiple sites, without tophus (tophi)
M1A.49X1	Other secondary chronic gout, multiple sites, with tophus (tophi)
M1A.9XX0	Chronic gout, unspecified, without tophus (tophi)
M1A.9XX1	Chronic gout, unspecified, with tophus (tophi)
M10.00	Idiopathic gout, unspecified site
M10.09	Idiopathic gout, multiple sites
M10.40	Other secondary gout, unspecified site
M10.49	Other secondary gout, multiple sites
M10.9	Gout, unspecified
N20.9	Urinary calculus, unspecified
Z48.811	Encounter for surgical aftercare following surgery on the nervous system
Z85.6	Personal history of leukemia
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues
Z85.9	Personal history of malignant neoplasm, unspecified
Z92.25	Personal history of immunosuppression therapy
Z92.3	Personal history of irradiation

Group 13 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Report ICD-10-CM code C49.9 with ICD-10-CM code Z92.21 to indicate prior chemotherapy.

Group 14

(2 Codes)

Group 14 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81377 and 81383.

Group 14 Codes

Code	Description
C50.919*	Malignant neoplasm of unspecified site of unspecified female breast
C50.929*	Malignant neoplasm of unspecified site of unspecified male breast

Group 14 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Report ICD-10-CM code C50.919 or C50.929 with ICD-10-CM codes Z15.01 and Z92.21 and/or Z92.22 OR

*Report ICD-10-CM code C50.919 with ICD-10-CM codes Z15.01, Z17.0, and Z79.890.

Group 15

(1 Code)

Group 15 Paragraph

The following ICD-10-CM code supports medical necessity and provides coverage for CPT code: 81401.

Group 15 Codes

Code	Description
T36.5X5A	Adverse effect of aminoglycosides, initial encounter

Group 16

(12 Codes)

Group 16 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT code: 81406.

Group 16 Codes

Code	Description
T41.0X5A	Adverse effect of inhaled anesthetics, initial encounter
T41.0X5D	Adverse effect of inhaled anesthetics, subsequent encounter
T41.0X5S	Adverse effect of inhaled anesthetics, sequela
T41.0X6A	Underdosing of inhaled anesthetics, initial encounter
T41.0X6D	Underdosing of inhaled anesthetics, subsequent encounter
T41.0X6S	Underdosing of inhaled anesthetics, sequela
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.1X5D	Adverse effect of intravenous anesthetics, subsequent encounter
T41.1X5S	Adverse effect of intravenous anesthetics, sequela
T41.1X6A	Underdosing of intravenous anesthetics, initial encounter
T41.1X6D	Underdosing of intravenous anesthetics, subsequent encounter
T41.1X6S	Underdosing of intravenous anesthetics, sequela

Group 17

(19 Codes)

Group 17 Paragraph

The following ICD-10-CM code supports medical necessity and provides coverage for CPT codes: 81479 for Gene Test CYP2B6, 0349U, 0392U, and 0423U.

Group 17 Codes

Code	Description
B20	Human immunodeficiency virus [HIV] disease
F32.1	Major depressive disorder, single episode, moderate
F32.2	Major depressive disorder, single episode, severe without psychotic features
F32.3	Major depressive disorder, single episode, severe with psychotic features
F32.4	Major depressive disorder, single episode, in partial remission
F32.81	Premenstrual dysphoric disorder
F32.9	Major depressive disorder, single episode, unspecified
F33.1	Major depressive disorder, recurrent, moderate
F33.2	Major depressive disorder, recurrent severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms
F33.41	Major depressive disorder, recurrent, in partial remission
F33.9	Major depressive disorder, recurrent, unspecified
F40.01	Agoraphobia with panic disorder
F40.11	Social phobia, generalized
F41.0	Panic disorder [episodic paroxysmal anxiety]
F41.1	Generalized anxiety disorder
F43.11	Post-traumatic stress disorder, acute
F43.12	Post-traumatic stress disorder, chronic
F60.5	Obsessive-compulsive personality disorder

Group 18

(40 Codes)

Group 18 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81479 for Gene Test CYP4F2 and 0349U.

Group 18 Codes

Code	Description
I21.9	Acute myocardial infarction, unspecified
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction
I25.2	Old myocardial infarction
I26.02	Saddle embolus of pulmonary artery with acute cor pulmonale
I26.03	Cement embolism of pulmonary artery with acute cor pulmonale
I26.04	Fat embolism of pulmonary artery with acute cor pulmonale
I26.09	Other pulmonary embolism with acute cor pulmonale
I26.92	Saddle embolus of pulmonary artery without acute cor pulmonale
I26.93	Single subsegmental thrombotic pulmonary embolism without acute cor pulmonale
I26.94	Multiple subsegmental thrombotic pulmonary emboli without acute cor pulmonale
I26.95	Cement embolism of pulmonary artery without acute cor pulmonale
I26.96	Fat embolism of pulmonary artery without acute cor pulmonale
I26.99	Other pulmonary embolism without acute cor pulmonale
I48.11	Longstanding persistent atrial fibrillation
I48.19	Other persistent atrial fibrillation
I48.20	Chronic atrial fibrillation, unspecified
I48.21	Permanent atrial fibrillation
I51.3	Intracardiac thrombosis, not elsewhere classified
I82.890	Acute embolism and thrombosis of other specified veins
I82.891	Chronic embolism and thrombosis of other specified veins
T82.817A	Embolism due to cardiac prosthetic devices, implants and grafts, initial encounter
T82.817D	Embolism due to cardiac prosthetic devices, implants and grafts, subsequent encounter
T82.817S	Embolism due to cardiac prosthetic devices, implants and grafts, sequela
T82.818A	Embolism due to vascular prosthetic devices, implants and grafts, initial encounter
T82.818D	Embolism due to vascular prosthetic devices, implants and grafts, subsequent encounter
T82.818S	Embolism due to vascular prosthetic devices, implants and grafts, sequela
T82.867A	Thrombosis due to cardiac prosthetic devices, implants and grafts, initial encounter
T82.867D	Thrombosis due to cardiac prosthetic devices, implants and grafts, subsequent encounter
T82.867S	Thrombosis due to cardiac prosthetic devices, implants and grafts, sequela
T82.868A	Thrombosis due to vascular prosthetic devices, implants and grafts, initial encounter
T82.868D	Thrombosis due to vascular prosthetic devices, implants and grafts, subsequent encounter
T82.868S	Thrombosis due to vascular prosthetic devices, implants and grafts, sequela
Z79.01	Long term (current) use of anticoagulants
Z79.02	Long term (current) use of antithrombotics/antiplatelets
Z86.711	Personal history of pulmonary embolism
Z86.718	Personal history of other venous thrombosis and embolism
Z86.79	Personal history of other diseases of the circulatory system
Z95.2	Presence of prosthetic heart valve
Z95.4	Presence of other heart-valve replacement

Group 19

(12 Codes)

Group 19 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT code: 81479 and Gene Test CACNA1S.

Group 19 Codes

Code	Description
T41.0X5A	Adverse effect of inhaled anesthetics, initial encounter
T41.0X5D	Adverse effect of inhaled anesthetics, subsequent encounter
T41.0X5S	Adverse effect of inhaled anesthetics, sequela
T41.0X6A	Underdosing of inhaled anesthetics, initial encounter
T41.0X6D	Underdosing of inhaled anesthetics, subsequent encounter
T41.0X6S	Underdosing of inhaled anesthetics, sequela
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.1X5D	Adverse effect of intravenous anesthetics, subsequent encounter
T41.1X5S	Adverse effect of intravenous anesthetics, sequela
T41.1X6A	Underdosing of intravenous anesthetics, initial encounter
T41.1X6D	Underdosing of intravenous anesthetics, subsequent encounter
T41.1X6S	Underdosing of intravenous anesthetics, sequela

Group 20

(6 Codes)

Group 20 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT code: 81479 and Gene Test BCHE.

Group 20 Codes

Code	Description
T41.1X5A	Adverse effect of intravenous anesthetics, initial encounter
T41.1X5D	Adverse effect of intravenous anesthetics, subsequent encounter
T41.1X5S	Adverse effect of intravenous anesthetics, sequela
T41.1X6A	Underdosing of intravenous anesthetics, initial encounter
T41.1X6D	Underdosing of intravenous anesthetics, subsequent encounter
T41.1X6S	Underdosing of intravenous anesthetics, sequela

Group 21

(22 Codes)

Group 21 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 81479 for Gene Test IFNL4 and 0349U.

Group 21 Codes

Code	Description
B18.0*	Chronic viral hepatitis B with delta-agent
B18.1*	Chronic viral hepatitis B without delta-agent
B18.2*	Chronic viral hepatitis C
C43.0*	Malignant melanoma of lip
C43.111*	Malignant melanoma of right upper eyelid, including canthus
C43.112*	Malignant melanoma of right lower eyelid, including canthus
C43.121*	Malignant melanoma of left upper eyelid, including canthus
C43.122*	Malignant melanoma of left lower eyelid, including canthus
C43.21*	Malignant melanoma of right ear and external auricular canal
C43.22*	Malignant melanoma of left ear and external auricular canal
C43.31*	Malignant melanoma of nose
C43.39*	Malignant melanoma of other parts of face
C43.4*	Malignant melanoma of scalp and neck
C43.51*	Malignant melanoma of anal skin
C43.52*	Malignant melanoma of skin of breast
C43.59*	Malignant melanoma of other part of trunk
C43.61*	Malignant melanoma of right upper limb, including shoulder
C43.62*	Malignant melanoma of left upper limb, including shoulder
C43.71*	Malignant melanoma of right lower limb, including hip
C43.72*	Malignant melanoma of left lower limb, including hip
C43.8*	Malignant melanoma of overlapping sites of skin
C43.9*	Malignant melanoma of skin, unspecified

Group 21 Medical Necessity ICD-10-CM Codes Asterisk Explanation

*Dual diagnosis requirement: ICD-10-CM code B18.0, B18.1, or B18.2 must be reported with ICD-10-CM code K76.9 to indicate compensated liver disease.

*Dual diagnosis requirement: ICD-10-CM code C43.0, C43.111, C43.112, C43.121, C43.122, C43.21, C43.22, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.61, C43.62, C43.71, C43.72, C43.8, or C43.9 must be reported with ICD-10-CM code C77.9 to indicate nodal involvement.

Group 22

(2 Codes)

Group 22 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT code: 81479 and Gene Test NAT2.

Group 22 Codes

Code	Description
G70.80	Lambert-Eaton syndrome, unspecified
G70.81	Lambert-Eaton syndrome in disease classified elsewhere

Group 23

(70 Codes)

Group 23 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT code: 81479 and Gene Test Nonspecific (NAT).

Group 23 Codes

Code	Description
A03.8	Other shigellosis
A03.9	Shigellosis, unspecified
A04.4	Other intestinal Escherichia coli infections
A15.9	Respiratory tuberculosis unspecified
A17.9	Tuberculosis of nervous system, unspecified
A18.01	Tuberculosis of spine
A18.02	Tuberculous arthritis of other joints
A18.03	Tuberculosis of other bones
A18.09	Other musculoskeletal tuberculosis
A18.10	Tuberculosis of genitourinary system, unspecified
A18.11	Tuberculosis of kidney and ureter
A18.12	Tuberculosis of bladder
A18.13	Tuberculosis of other urinary organs
A18.14	Tuberculosis of prostate
A18.15	Tuberculosis of other male genital organs
A18.16	Tuberculosis of cervix
A18.17	Tuberculous female pelvic inflammatory disease
A18.18	Tuberculosis of other female genital organs
A18.2	Tuberculous peripheral lymphadenopathy
A18.31	Tuberculous peritonitis
A18.32	Tuberculous enteritis
A18.39	Retroperitoneal tuberculosis
A18.4	Tuberculosis of skin and subcutaneous tissue
A18.50	Tuberculosis of eye, unspecified
A18.51	Tuberculous episcleritis
A18.52	Tuberculous keratitis
A18.53	Tuberculous chorioretinitis
A18.54	Tuberculous iridocyclitis
A18.59	Other tuberculosis of eye
A18.6	Tuberculosis of (inner) (middle) ear
A18.7	Tuberculosis of adrenal glands
A18.81	Tuberculosis of thyroid gland
A18.82	Tuberculosis of other endocrine glands
A18.83	Tuberculosis of digestive tract organs, not elsewhere classified
A18.84	Tuberculosis of heart
A18.85	Tuberculosis of spleen
A18.89	Tuberculosis of other sites
A19.8	Other miliary tuberculosis
A19.9	Miliary tuberculosis, unspecified
B20	Human immunodeficiency virus [HIV] disease
B59	Pneumocystosis
B96.20	Unspecified Escherichia coli [E. coli] as the cause of diseases classified elsewhere
D84.89	Other immunodeficiencies
D84.9	Immunodeficiency, unspecified
E46	Unspecified protein-calorie malnutrition
H66.90	Otitis media, unspecified, unspecified ear
H66.93	Otitis media, unspecified, bilateral
J42	Unspecified chronic bronchitis
J62.8	Pneumoconiosis due to other dust containing silica
K27.4	Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.5	Chronic or unspecified peptic ulcer, site unspecified, with perforation
K27.6	Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.7	Chronic peptic ulcer, site unspecified, without hemorrhage or perforation
K27.9	Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation
K51.90	Ulcerative colitis, unspecified, without complications
K51.918	Ulcerative colitis, unspecified with other complication
K51.919	Ulcerative colitis, unspecified with unspecified complications
N18.6	End stage renal disease
N39.0	Urinary tract infection, site not specified
Z20.1	Contact with and (suspected) exposure to tuberculosis
Z20.6	Contact with and (suspected) exposure to human immunodeficiency virus [HIV]
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status
Z22.7	Latent tuberculosis
Z85.6	Personal history of leukemia
Z85.819	Personal history of malignant neoplasm of unspecified site of lip, oral cavity, and pharynx
Z86.39	Personal history of other endocrine, nutritional and metabolic disease
Z90.3	Acquired absence of stomach [part of]
Z92.241	Personal history of systemic steroid therapy
Z92.25	Personal history of immunosuppression therapy
Z98.84	Bariatric surgery status

Group 24

(7 Codes)

Group 24 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 0193U and 0423U.

Group 24 Codes

Code	Description
E78.00	Pure hypercholesterolemia, unspecified
E78.01	Familial hypercholesterolemia
E78.1	Pure hyperglyceridemia
E78.2	Mixed hyperlipidemia
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
Z86.79	Personal history of other diseases of the circulatory system

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

All those not listed under the “ICD-10-CM Codes that Support Medical Necessity” section of this article.

Group 1 Codes

N/A

ICD-10-PCS Codes

N/A

Additional ICD-10 Information

N/A

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

Code	Description
Please accept the License to see the codes.

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

Code	Description
Please accept the License to see the codes.

Other Coding Information

N/A

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

Revision History Date	Revision History Number	Revision History Explanation
10/24/2024	R11	Article revised and published on 10/24/2024. In response to the annual ICD-10-CM Code Update the following ICD-10-CM codes have been added to ICD-10-CM Codes That Support Medical Necessity Group 18: I26.03, I26.04, I26.95, and I26.96 effective for dates of service on and after 10/01/2024. The following ICD-10-CM codes had a code descriptor change: I26.96 and I26.94 effective for dates of service on and after 10/01/2024. Additionally, CPT code 0349U has been added to the article for Table 1 (CPIC) for CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, IFNL4, HLA-A, HLA-B, NUDT15, SLCO1B1, TPMT, and UGT1A1 and to Table 2 (FDA) for CYP2B6, CYP2C19 and/or UGT2B17, CYP2C9, CYP2D6, CYP4F2, DPYD, HLA-A, HLA-B, SLCO1B1, NUDT15 and/or TPMT, and UGT1A1 effective for dates of service on and after 10/24/2024. Lastly, the rows in Table 1 and Table 2 for CYP2CP (81227) and VKORC1 (81355) specific to warfarin have been removed as they are not considered reasonable and necessary for warfarin testing.
01/01/2024	R10	Article revised and published on 01/25/2024 effective for dates of service on and after 01/01/2024 to reflect the Annual CPT/HCPCS Updates. CPT code 0423U has been added to the article for Table 1 (CPIC) for ABCG2/0193U and CYP2B6/81479, 0392U, and for Table 1 (CPIC) and Table 2 (FDA) for CYP3A5/81231; CYP2B6/81479; CYP2C19/81225, 81418; CYP2C9/81227; CYP2D6/81226, 81418, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U; CYP2D6/81226, 81418; HLA-B/81381, 81374 and SLCO1B1/81328. CPT code 0423U has been added to the article for the following CPT and ICD-10-CM Code Groups: 2, 3, 4, 5, 6, 11, 13, 17 and 24. For the following CPT codes either the short description and/or the long description was changed. Depending on which description is used in this article, there may not be any change in how the code displays: 81406 (CPT Group 16 Codes), 81407 and 81408 (CPT Group 25 Codes).
10/01/2023	R9	Article revised and published on 10/26/2023 effective for dates of service on and after 10/01/2023 to reflect the Annual ICD-10-CM Code Updates. The following ICD-10-CM code has been added to the article: I21.B in Code Group 2.
07/01/2023	R8	Article revised and published on 07/20/2023 effective for dates of service on and after 07/01/2023 in response to the July HCPCS Quarterly Update. The following drugs have been added to Table 1 (CPIC): sertraline (CYP2B6/81479, 0392U) and venlafaxine and vortioxetine (CYP2D6/81226, 81418, 0392U). The following CPT code has been added to the Article in the ‘CPT/HCPCS Codes’ section: 0392U in Code Groups 4 and 17. The ‘ICD-10-CM Codes that Support Medical Necessity’ section has been revised to add ICD-10-CM codes as follows: Code Groups 2 and 3: F32.81; Code Group 4: F40.01, F40.11, F41.0, F41.1, F43.11, F43.12 and F60.5; and Code Group 17: F32.1, F32.2, F32.3, F32.4, F32.81, F32.9, F33.1, F33.2, F33.3, F33.41, F33.9, F40.01, F40.11, F41.0, F41.1, F43.11, F43.12 and F60.5.
04/27/2023	R7	Article revised and published on 04/27/2023 effective for dates of service on and after 01/01/2022 to remove CPT codes 0289U through 0294U from the CPT/HCPCS Code Group 25 that were erroneously added in January 2022.
03/09/2023	R6	Article revised and published on 03/09/2023 effective for dates of service on and after 10/26/2022 to update the article from CPIC and FDA sources. The following drugs have been added to Table 1 (CPIC): dapsone, methylene blue, nitrofurantoin, pegloticase, primaquine, tafenoquine (G6PD/81247) and nateglinide has been added to Table 2 (FDA) (CYP2C9/81227). The following ICD-10-CM codes were added to the ‘ICD-10-CM Codes that Support Medical Necessity’ section for Code Group 5: T38.3X5A and for Code Group 8: B51.0, B51.8, B51.9, D74.8, L70.0, M1A.0110, M1A.0111, M1A.0120, M1A.0121, M1A.0210, M1A.0211, M1A.0220, M1A.0221, M1A.0310, M1A.0311, M1A.0320, M1A.0321, M1A.0410, M1A.0411, M1A.0420, M1A.0421, M1A.0510, M1A.0511, M1A.0520, M1A.0521, M1A.0610, M1A.0611, M1A.0620, M1A.0621, M1A.0710, M1A.0711, M1A.0720, M1A.0721, M1A.08X0, M1A.08X1, M1A.09X0, M1A.09X1, M1A.1110, M1A.1111, M1A.1120, M1A.1121, M1A.1210, M1A.1211, M1A.1220, M1A.1221, M1A.1310, M1A.1311, M1A.1320, M1A.1321, M1A.1410, M1A.1411, M1A.1420, M1A.1421, M1A.1510, M1A.1511, M1A.1520, M1A.1521, M1A.1610, M1A.1611, M1A.1620, M1A.1621, M1A.1710, M1A.1711, M1A.1720, M1A.1721, M1A.18X0, M1A.18X1, M1A.19X0, M1A.19X1, M1A.2110, M1A.2111, M1A.2120, M1A.2121, M1A.2210, M1A.2211, M1A.2220, M1A.2221, M1A.2310, M1A.2311, M1A.2320, M1A.2321, M1A.2410, M1A.2411, M1A.2420, M1A.2421, M1A.2510, M1A.2511, M1A.2520, M1A.2521, M1A.2610, M1A.2611, M1A.2620, M1A.2621, M1A.2710, M1A.2711, M1A.2720, M1A.2721, M1A.28X0, M1A.28X1, M1A.29X0, M1A.29X1, M1A.3110, M1A.3111, M1A.3120, M1A.3121, M1A.3210, M1A.3211, M1A.3220, M1A.3221, M1A.3310, M1A.3311, M1A.3320, M1A.3321, M1A.3410, M1A.3411, M1A.3420, M1A.3421, M1A.3510, M1A.3511, M1A.3520, M1A.3521, M1A.3610, M1A.3611, M1A.3620, M1A.3621, M1A.3710, M1A.3711, M1A.3720, M1A.3721, M1A.38X0, M1A.38X1, M1A.39X0, M1A.39X1, M1A.4110, M1A.4111, M1A.4120, M1A.4121, M1A.4210, M1A.4211, M1A.4220, M1A.4221, M1A.4310, M1A.4311, M1A.4320, M1A.4321, M1A.4410, M1A.4411, M1A.4420, M1A.4421, M1A.4510, M1A.4511, M1A.4520, M1A.4521, M1A.4610, M1A.4611, M1A.4620, M1A.4621, M1A.4710, M1A.4711, M1A.4720, M1A.4721, M1A.48X0, M1A.48X1, M1A.49X0, M1A.49X1, N30.00* and N30.01* (with associated asterisk note). An asterisk note has also been added to ICD-10-CM Code Group 4 for ICD-10 code R11.2*.
01/01/2023	R5	Article revised and published on 01/26/2023 effective for dates of service on and after 01/01/2023 to reflect the Annual HCPCS/CPT Code Updates. The ‘Coding Guidance’ section has been revised to add coding information for CPT code 81418. CPT code 81418 was added to Table 1 (CPIC) and Table 2 (FDA) for genes CYP2C19 and CYP2D6. Hydrocodone was also added to Table 1 (CPIC) for CYP2D6. Abrocitnib, mavacamten and belzutifan were added to Table 2 (FDA) for CYP2C19. The following CPT code has been added to the Article: 81418 in Code Groups 2, 3, and 4. The following ICD-10-CM codes were added to the ‘ICD-10-CM Codes that Support Medical Necessity’ section for Code Group 2: C25.4, C64.1, C64.2, C65.1, C65.2, C66.1, C66.2, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C68.0, C68.1, C68.8, C7A.093, D13.7, D18.02, D32.0, D32.1, D33.0, D33.1, D33.3, D33.4, D33.7*, I42.1, and L20.89 with associated asterisk note. Also, the Affected Subgroups in Table 2 was updated for pantoprazole, irinotecan and tramadol.
10/01/2022	R4	Article revised and published on 10/20/2022 effective for dates of service on and after 10/01/2022 to reflect the Annual ICD-10-CM Code Updates. For the following ICD-10-CM codes the code description has changed: C84.40 and C84.48 in Group 12.
02/07/2022	R3	Article revised and published on 08/04/2022 in response to an inquiry to update the article from CPIC and FDA sources. The following drugs and associated genes and CPT codes were added to Table 1 (CPIC): fosphenytoin, fluvastatin (CYP2C9/81227), fosphenytoin (HLA-B/81381, 81374), tramadol (CYP2D6/81226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U), peginterferon alfa-2a, peginterferon alfa-2b (IFNL4/81479), pravastatin, atorvastatin, lovastatin, rosuvastatin, fluvastatin, pitavastatin (SLCO1B1/81328), gentamicin, amikacin, paromomycin, streptomycin, plazomicin, tobramycin (MT-RNR1/81401), and rosuvastatin (ABCG2/0193U). The following drugs were deleted from Table 1: aspirin, diclofenac, aceclofenac, indomethacin, lumiracoxib, metamizole, nabumetone, naproxen, tegafur, and ribavirin. The following drugs and associated genes and CPT codes were added to Table 2 (FDA): voriconazole (CYP2C19/81225), fosphenytoin, meloxicam, phenytoin (CYP2C9/81227), oliceridine, pitolisant (CYP2D6/81226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U), fosphenytoin, phenytoin (HLA-B/81381, 81374), and sacituzumab govitecan-hziy (UGT1A1/81350). The ‘Affected Subgroups’ column in Table 2 was revised for the following drugs: celecoxib (CYP2C9/81227) and flurbiprofen (CYP2C9/81227). The ‘CPT/HCPCS Codes’ and ‘ICD-10-CM Codes that Support Medical Necessity’ sections were revised to add the following new groups effective for dates of service on and after 02/07/2022: ‘Group 15’ for CPT code 81401, ‘Group 21’ for CPT code 81479 and gene test IFNL4, and ‘Group 24’ for CPT code 0193U and all subsequent groups were renumbered accordingly in both sections. The ‘ICD-10-CM Codes that Support Medical Necessity’ section has been revised to add ICD-10 codes as follows effective for dates of service on and after 12/12/2021: Group 2 for 81225 (B48.8* with an associated asterisk note), Group 3 for 81226, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, and 0076U (G47.411 and G47.419), Group 5 for 81227 (E78.00, E78.01, E78.1, E78.2, I25.10, M06.8A, M19.09, M19.29, Z86.73, and Z86.79, Group 9 for 81283 (B18.0, B18.1, B18.2, C43.0, C43.111, C43.112, C43.121, C43.122, C43.21, C43.22, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.61, C43.62, C43.71, C43.72, C43.8, and C43.9 with associated asterisk notes), Group 11 for 81328 (E11.8, E11.9, I25.10, and associated asterisk note), and Group 12 for 81350 (C50.011, C50.012, C50.021, C50.022, C50.111, C50.112, C50.121, C50.122, C50.211, C50.212, C50.221, C50.222, C50.311, C50.312, C50.321, C50.322, C50.411, C50.412, C50.421, C50.422, C50.511, C50.512, C50.521, C50.522, C50.611, C50.612, C50.621, C50.622, C50.811, C50.812, C50.821, C50.822, C65.1, C65.2, C66.1, C66.2, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, C68.0, and C68.8 with associated asterisk notes). Minor formatting changes have been made throughout the coding section.
01/01/2022	R2	Article revised and published on 01/20/2022 effective for dates of service on and after 01/01/2022 to reflect the Annual HCPCS/CPT Code Updates. The following CPT codes have been added to the Article: 0286U in Table 1 for Gene/Test NUDT15, Table 2 for Gene NUDT15 and/or TPMT, ‘CPT/HCPCS Codes’ section for ‘Group 10 Codes’, and ‘ICD-10-CM Codes that Support Medical Necessity’ section for ‘Group 10 Paragraph’ and 0289U, 0290U, 0291U, 0292U, 0293U, and 0294U in the ‘CPT/HCPCS Codes’ section for ‘Group 22 Codes’.
12/12/2021	R1	Article revised and published on 12/09/2021 effective for dates of service on and after 12/12/2021. A paragraph was added to the ‘Coding Guidance’ section to address CPT codes 81355 (VKORC1) and 81227 (CYP2C9) not considered medically reasonable and necessary for warfarin testing with reference to NCD 90.1. The ‘ICD-10-CM Codes that Support Medical Necessity, Group 5’ for CPT code 81227 was revised to remove ICD-10 codes in this regard. This group was also revised to add ICD-10 codes in relation to Gene/Test CYP2C9 for phenytoin. The sections for ‘CPT/HCPCS Codes’ and ‘ICD-10-CM Codes that Support Medical Necessity’, for ‘Group 13’ were deleted for CPT code 81355 and all subsequent groups were renumbered accordingly in both sections. CPT code 81355 was added to the ‘CPT codes Non-Covered for pharmacogenomic testing’ (Group 22). A ‘CPT/HCPCS Modifier Table’ was added to include modifier 59.

Associated Documents

Updated On	Effective Dates	Status
10/18/2024	10/24/2024 - N/A	Currently in Effect	You are here
01/19/2024	01/01/2024 - 10/23/2024	Superseded	View
10/20/2023	10/01/2023 - 12/31/2023	Superseded	View
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A

Read the Article Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Billing and Coding: Pharmacogenomics Testing

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

CPT/HCPCS Codes

Please accept the License to see the codes.

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

Group 8

Group 9

Group 10

Group 11

Group 12

Group 13

Group 14

Group 15

Group 16

Group 17

Group 18

Group 19

Group 20

Group 21

Group 22

Group 23

Group 24

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Billing and Coding: Pharmacogenomics Testing (A58812)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS